Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (CUE) on October 3, 2019. The filing reports a change in the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Resignation: Anthony DiGiandomenico resigned as a member of the Board of Directors on October 3, 2019. The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Board Appointment: Dr. Aaron Fletcher was appointed to the Board of Directors on October 3, 2019, to replace Mr. DiGiandomenico.
Management Commentary and Compensation
Dr. Fletcher brings significant experience in healthcare equity research and venture capital, having founded Bios Research and serving as Managing Partner of Bios Partners, LP. He also serves on the boards of several other biotechnology and life science companies.
Compensation Arrangements:
- Annual cash retainer: $35,000.
- Annual stock option award: 8,000 shares of common stock.
- Initial appointment award: Options to purchase 50,000 shares of common stock, vesting in eight equal semi-annual installments.
Key Facts for Investor Verification
- Confirm the vesting schedule and exercise price for the 50,000 initial option grant to Dr. Fletcher.
- Verify the total number of outstanding shares and the potential dilution impact of the new director options.
- Review the Company's most recent 10-Q or 10-K for current financial status, as this 8-K contains no financial metrics.